Qubit Pharmaceuticals
Qubit Pharmaceuticals designs new drugs using molecular modeling accelerated by hybrid HPC and quantum computing.
Overview
Qubit Pharmaceuticals is a trailblazing deep tech company specializing in the discovery and design of new drug candidates for complex targets, including RNA. It relies on cutting-edge technologies in molecular simulation, hybrid high-performance computing (HPC) and artificial intelligence (AI).
Thanks to its technologies and expertise, Qubit Pharmaceuticals is advancing seven proprietary and partnered drug discovery programs, with a particular focus on oncology, chronic inflammatory diseases and RNA-related targets. Its proprietary drug discovery platform, ATLAS, is based on 30 years of research conducted by its scientific founders and continually enriched and optimized.
Founded in 2020, the company raised €16 million in 2022 to accelerate its groundbreaking research and development.
The team
The founding team includes Louis Lagardère (research engineer at Sorbonne University), Matthieu Montes (professor of bioinformatics at Cnam), Jean-Philip Piquemal (scientific director and professor of theoretical chemistry at Sorbonne University), Jay Ponder (professor of chemistry, biochemistry and molecular biophysics, and biomedical engineering at Washington University in St. Louis) and Pengyu Ren (professor at the University of Texas at Austin.)